Latest news with #Apotex
Cision Canada
20-05-2025
- Business
- Cision Canada
Apotex publishes 2024 Sustainability Report, highlighting progress and achievements in environmentally sustainable manufacturing, responsible business practices, and social impact
TORONTO, May 20, 2025 /CNW/ - Apotex Inc. ("Apotex"), the Canadian-based global health company, today published its 2024 Sustainability Report, showcasing its ongoing commitment to sustainable, responsible business practices and its global impact. Apotex's 2024 Sustainability Report underscores our commitment to advancing health and unlocking new possibilities through partnerships, while championing sustainability and responsible business practices. As we continue to execute our Journey of Health growth strategy, our focus on sustainability ensures that we are meeting the needs of patients, physicians, and pharmacists, and contributing positively to the environment and society. This report reflects our dedication to these values, and to transparency, accountability, and long-term value creation," said Allan Oberman, President & CEO, Apotex. Key achievements include: Sourcing 81% of global electricity consumption from renewable or low-carbon sources in 2024 and significant reductions in Scope 1 and 2 emissions through the implementation of energy-efficient technologies across our facilities More than $1.5 million in essential products donated to vulnerable populations in 2024, and the establishment of the Apotex Global Health Access Fund, which provides long-term funding to support maternal health initiatives in Canada, the United States, Mexico, and India Enhancement of Apotex's Global Risk Management Program and strengthening the Global Business Ethics and Compliance Program to further enhance transparency and accountability Hiring a new Head of Sustainability to further advance Apotex's enterprise-wise ESG strategy Apotex has also made strides in waste management, achieving notable reductions in waste generation by applying green chemistry principles and innovative recycling programs, and aims to continue implementing energy-efficient technologies and renewable energy solutions to further reduce its environmental footprint. Learn more about sustainability at Apotex. About Apotex Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people worldwide, with a broad portfolio of generic, biosimilar, innovative branded pharmaceuticals and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Learn more about us at
Yahoo
20-05-2025
- Business
- Yahoo
Apotex publishes 2024 Sustainability Report, highlighting progress and achievements in environmentally sustainable manufacturing, responsible business practices, and social impact
TORONTO, May 20, 2025 /PRNewswire/ - Apotex Inc. ("Apotex"), the Canadian-based global health company, today published its 2024 Sustainability Report, showcasing its ongoing commitment to sustainable, responsible business practices and its global impact. Apotex's 2024 Sustainability Report underscores our commitment to advancing health and unlocking new possibilities through partnerships, while championing sustainability and responsible business practices. As we continue to execute our Journey of Health growth strategy, our focus on sustainability ensures that we are meeting the needs of patients, physicians, and pharmacists, and contributing positively to the environment and society. This report reflects our dedication to these values, and to transparency, accountability, and long-term value creation," said Allan Oberman, President & CEO, Apotex. Key achievements include: Sourcing 81% of global electricity consumption from renewable or low-carbon sources in 2024 and significant reductions in Scope 1 and 2 emissions through the implementation of energy-efficient technologies across our facilities More than $1.5 million in essential products donated to vulnerable populations in 2024, and the establishment of the Apotex Global Health Access Fund, which provides long-term funding to support maternal health initiatives in Canada, the United States, Mexico, and India Enhancement of Apotex's Global Risk Management Program and strengthening the Global Business Ethics and Compliance Program to further enhance transparency and accountability Hiring a new Head of Sustainability to further advance Apotex's enterprise-wise ESG strategy Apotex has also made strides in waste management, achieving notable reductions in waste generation by applying green chemistry principles and innovative recycling programs, and aims to continue implementing energy-efficient technologies and renewable energy solutions to further reduce its environmental footprint. Learn more about sustainability at Apotex. About Apotex Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people worldwide, with a broad portfolio of generic, biosimilar, innovative branded pharmaceuticals and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Learn more about us at View original content to download multimedia: SOURCE Apotex Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Cision Canada
09-05-2025
- Business
- Cision Canada
Apotex introduces IVRA™ (Melphalan) hydrochloride injection: First ready to dilute liquid formulation of Melphalan injection approved via 505(b)(2) NDA in the United States
WESTON, Fla., May 9, 2025 /CNW/ - Apotex Corp. today launched IVRA™ (Melphalan) hydrochloride injection 90mg/ml multidose vial ("IVRA"), first ready-to-dilute liquid formulation of Melphalan injection approved via 505(b)(2) NDA in the United States. IVRA is an alkylating drug indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate, and will be distributed primarily through hospital and institutional channels. "The launch of IVRA highlights Apotex's uncompromising dedication to access, innovation, and patient care," said Christine Baeder, President, Apotex USA. "As we introduce our novel ready-to-dilute liquid formulation of Melphalan injection approved via 505(b)(2) NDA in the United States, we reinforce our commitment to bringing much-needed products that support patients on their health journeys." Please refer to the complete prescribing information, patient information leaflet, warnings and precautions, adverse reactions, and contraindications. About Apotex Apotex Corp., headquartered in Weston, Florida, is an affiliate of Apotex Inc. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic and innovative pharmaceutical and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Learn more about us at SOURCE Apotex Inc.
Yahoo
06-05-2025
- Business
- Yahoo
Formosa Pharmaceuticals Announces Licensing Agreement with Apotex Inc., for Commercialization of Clobetasol Propionate Ophthalmic Suspension for Post-Ocular Surgery Inflammation and Pain for Mexico
TAIPEI, May 6, 2025 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", announced today that the company has entered into an exclusive licensing agreement with Apotex Inc. ("Apotex"), for exclusive rights in Mexico for the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a patented innovative medicine for the treatment of inflammation and pain following ocular surgery. Clobetasol propionate ophthalmic suspension, 0.05% (APP13007) was approved by the U.S. Food and Drug Administration (FDA) in 2024. APP13007's active ingredient is the superpotent corticosteroid, clobetasol propionate, and is derived from Formosa Pharma's proprietary APNT® nanoparticle formulation platform. The novel formulation enables a convenient and straightforward dosing regimen, while providing rapid and sustained relief of inflammation and pain, which in Phase 3 trials proved statistically and clinically superior to its matching placebo (p<0.001). (PRNewsfoto/Formosa Pharmaceuticals Inc.,) "Having started our journey together in 2024, Formosa Pharma is pleased to expand the partnership with Apotex to include Mexico." said Erick Co, President and CEO of Formosa Pharmaceuticals. "Our experience with Apotex's Canadian team underscored their commitment to branded and differentiated ophthalmology products, giving us full confidence that APP13007 will reach ophthalmologists and patients in Mexico as swiftly as possible." "At Apotex, we are committed to delivering access to medicines and health products, and unlocking new possibilities for patients through partnerships. We are pleased to bring access to APP13007 (clobetasol propionate ophthalmic suspension, 0.05%) to the Mexican market upon regulatory approval. Our agreement with Formosa Pharmaceuticals further demonstrates Apotex's leading position as partner of choice in the Americas for pharmaceutical licensing and product acquisitions as we continue to execute our Journey of Heath growth strategy," said Alok Kanti, President, Apotex International. About Formosa Pharmaceuticals, Inc. Formosa Pharmaceuticals, Inc. ( is a clinical stage biotechnology company with primary focus in the areas of ophthalmology and oncology. The company's proprietary nanoparticle formulation technology (APNT®), through which APP13007 was developed, improves the dissolution and bioavailability of APIs for topical, oral, and inhaler administration. Resulting formulations have high uniformity, purity, and stability, thereby allowing the utilization of poorly soluble or extremely potent drug agents which otherwise may face insurmountable challenges in delivery and penetration to target tissues. For more details about Formosa Pharma and APNT®, visit
Malaysian Reserve
06-05-2025
- Business
- Malaysian Reserve
Formosa Pharmaceuticals Announces Licensing Agreement with Apotex Inc., for Commercialization of Clobetasol Propionate Ophthalmic Suspension for Post-Ocular Surgery Inflammation and Pain for Mexico
TAIPEI, May 6, 2025 /PRNewswire/ — Taiwan-based Formosa Pharmaceuticals ('Formosa', announced today that the company has entered into an exclusive licensing agreement with Apotex Inc. ('Apotex'), for exclusive rights in Mexico for the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a patented innovative medicine for the treatment of inflammation and pain following ocular surgery. Clobetasol propionate ophthalmic suspension, 0.05% (APP13007) was approved by the U.S. Food and Drug Administration (FDA) in 2024. APP13007's active ingredient is the superpotent corticosteroid, clobetasol propionate, and is derived from Formosa Pharma's proprietary APNT® nanoparticle formulation platform. The novel formulation enables a convenient and straightforward dosing regimen, while providing rapid and sustained relief of inflammation and pain, which in Phase 3 trials proved statistically and clinically superior to its matching placebo (p<0.001). 'Having started our journey together in 2024, Formosa Pharma is pleased to expand the partnership with Apotex to include Mexico.' said Erick Co, President and CEO of Formosa Pharmaceuticals. 'Our experience with Apotex's Canadian team underscored their commitment to branded and differentiated ophthalmology products, giving us full confidence that APP13007 will reach ophthalmologists and patients in Mexico as swiftly as possible.' 'At Apotex, we are committed to delivering access to medicines and health products, and unlocking new possibilities for patients through partnerships. We are pleased to bring access to APP13007 (clobetasol propionate ophthalmic suspension, 0.05%) to the Mexican market upon regulatory approval. Our agreement with Formosa Pharmaceuticals further demonstrates Apotex's leading position as partner of choice in the Americas for pharmaceutical licensing and product acquisitions as we continue to execute our Journey of Heath growth strategy,' said Alok Kanti, President, Apotex International. About Formosa Pharmaceuticals, Inc. Formosa Pharmaceuticals, Inc. ( is a clinical stage biotechnology company with primary focus in the areas of ophthalmology and oncology. The company's proprietary nanoparticle formulation technology (APNT®), through which APP13007 was developed, improves the dissolution and bioavailability of APIs for topical, oral, and inhaler administration. Resulting formulations have high uniformity, purity, and stability, thereby allowing the utilization of poorly soluble or extremely potent drug agents which otherwise may face insurmountable challenges in delivery and penetration to target tissues. For more details about Formosa Pharma and APNT®, visit About Apotex Inc. Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people worldwide, with a broad portfolio of generic, biosimilar, and innovative pharmaceutical and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Learn more about us at View original content to download multimedia: SOURCE Formosa Pharmaceuticals Inc.,
